806 results about "In vivo experiment" patented technology

The invention relates to a ursolic acid-aspirin conjugate shown in a formula (I) and application thereof in preparing drugs for preventing tumor metastasis. In vivo experiments verify that the ursolic acid-aspirin conjugate provided by the invention has a remarkable inhibitory effect on adhesion, migration, invasion and the like of tumor cells. in vivo animal experiments verify that the ursolic acid-aspirin conjugate can be used for reducing experimental pulmonary metastasis of 4T1 breast cancer of a rat and showing a relatively good tumor metastasis resisting effect. The ursolic acid-aspirin conjugate provided by the invention can be applied to preventive drugs for tumor metastasis, thereby providing novel selection for developing new drugs for tumor metastasis and preventing postoperative retransfer of malignant tumors. The formula (I) is shown in the description.

Contrast agents incorporating super-paramagnetic iron-oxide (SPIO) nanoparticles have shown promise as a means to visualize labeled cells using MRI. Labeled cells cause significant signal dephasing due to the magnetic field inhomogeneity induced in water molecules near the cell. With the resulting signal void as the means for detection, the particles are behaving as a negative contrast agent, which can suffer from partial-volume effects. Disclosed is a new method for imaging labeled cells with positive contrast. Spectrally-selective RF pulses are used to excite and refocus the off-resonance water surrounding the labeled cells so that only the fluid and tissue immediately adjacent to the labeled cells are visible in the image. Phantom, in vitro, and in vivo experiments show the feasibility of the new method. A significant linear correlation (r=0.87, p<0.005) between the estimated number of cells and the signal has been observed.

The invention relates to an intracellular triggering reduction sensitive drug linked gene targeted co-carrier which is a gene and drug double-loaded system and comprises disulfide bond cross-linked polyethylene imine, a poly-lactide glycolide copolymer and a surface modified targeted micromolecule. According to the invention, the surface modified active targeted group of a carrier can target drugs to a tumor part and enrich the drugs; a disulfide bond cross-linked in a polymer can be broken in a cell under the condition of high reduction, and the structure of the carrier is disassembled so that the drugs are released. The intracellular triggering reduction sensitive drug linked gene targeted co-carrier disclosed by the invention can effectively load the gene and the hydrophobic micromolecular drug, ensure the stability of the gene and is degraded and releases the gene and the micromolecular drug under the condition of reduction. An in-vivo experiment shows that the intracellular triggering reduction sensitive drug linked gene targeted co-carrier disclosed by the invention has outstanding targeting on tumors.

The invention relates to the technical field of medicines, and provides application of metrn1 protein in preparation of a lipid-lowering drug or a health-care food. An in vivo experiment shows that the blood lipid level of metrn1 fat cell specificity overexpression mice is obviously lower than that of normal mice when the normal mice and the metrn1 fat cell specificity overexpression mice are supplied with triglyceride lavage; the result shows that the metrn1 protein has an effect of reducing blood lipid. The metrn1 protein is intrinsic protein of a human body. Therefore, the safety of the metrn1 protein as a potential drug is high.

The invention provides a tonka bean ethers compound extracted from Compositae plants, the pharmaceutical composition containing the composition, and the use in treating antirheumatic or rheumatoid arthritis, and osteoarthritis. Extracorporal and animal in vivo experiment shows that, the compound can effectively treat and improve the symptoms for these diseases.

The invention relates to the technical field of immunotherapy of infectious diseases, in particular to recombinant gene construction of chimeric antigen receptor (CAR) for treating HIV (human immunodeficiency virus) infection and an application of the CAR. A single-chain antibody (ScFv) can identify gp120 of surfaces of HIV infected cells through series connection of antibody light chain and heavy chain variable zones of the gp120 of the surfaces of the HIV infected cells; the ScFv is prepared into the CAR, CAR coding genes are shifted to plasimid vectors, and lentiviral vectors shifted with the CAR coding genes are transduced to CD8+T lymphocytes. The CD8+T lymphocytes are discovered to be remarkable in restraining and killing activities of the HIV infected cells in both in-vitro and in-vivo experiments and can serve as active ingredients to prepare anti-HIV infection drugs, and good application prospect is achieved.

The invention relates to the separation and extraction methods of a sweet tea polyphenols. The invention uses integration of ultrafiltration with resin adsorption separation technique. Only ethanol is used as organic solvent during producing process and the separation technique of sweet tea polyphenols is optimized; the simple operation helps realize industrialized production; besides, the production process accords with environment protection requirement and the products accord with food and drug raw material requirements. The invention uses Guangxi sweet tea as raw materials to produce sweet tea polyphenols containing over 50% and 90%. Hyaluronidase inhibition in vitro experiment, in vivo experiments of mice passive dermato-allergic reaction and the delayed cutaneous hypersensitivity caused by dinitro-chlorobenzene confirm the invention has significant anti-anaphylaxis activity.

The invention relates to a drug release measuring device and a drug release measuring method which are provided for an endovescular stent. The invention solves the problem that the existing measuring device cannot simulate the condition within a human body or measure the deposition and distribution of the drug on vascular tissues. The method mainly comprises: a buffer solution is prepared; an animal vessel is separated and fixed, the stent is implanted and expanded, and a flow environment within the body is simulated; and samples are collected and tested. The measuring device comprises a reservoir, a silicone tube, a glass tube, a vessel implantation groove, a diaphragm capsule dilatometer, a flow valve, a high pressure gas cylinder and a peristaltic pump, wherein, the reservoir is connected with the vessel container by the glass tube; the vessel implantation groove is connected with the reservoir by the glass tube which contains the diaphragm capsule dilatometer and the flow valve; the reservoirs are connected together by the silicone tube which is provided with the peristaltic pump; the high pressure gas cylinder is connected with the reservoir by the silicone tube. The invention can not only simulate the flow condition within body accurately which can provide better support for the vivo experiment, but also measure the deposition and distribution of the drug on the vasculartissues.

The invention belongs to the field of pharmaceutical chemistry and in particular relates to an application of a specific piperidone-containing single-carbonyl curcumin compound in preparation of an anti-inflammatory drug and medicines used for treating related inflammation diseases. The curcumin compound can inhibit expression and release of an inflammation-suppressing factor IL-6, obviously reverse degradation of I kappa B related to regulation of inflammation and inhibit phosphorylation of inflammation signal channels such as ERK and JNK; and in vivo experiments show the curcumin compound can obviously improve survival rate of mice which are about to die owning to induction by virtue of LPS (lean process solution).